Pelvic Inflammatory Disease (PID) - Treatment

When to Hospitalize

• Surgical emergency (e.g., appendicitis) cannot be excluded
• Tubo-ovarian abscess (TOA) is present
• Pregnancy
• Severe illness: high fever, nausea, vomiting
• Unable to tolerate or follow an oral outpatient regimen
• No clinical response to oral therapy within 72 hours

Outpatient (IM/Oral) Regimens

Preferred Regimen A

Preferred Regimen B

Alternative Outpatient

• Another parenteral 3rd-generation cephalosporin (e.g., cefotaxime) + doxycycline 100 mg PO twice daily × 14 days ± metronidazole 500 mg twice daily × 14 days

Metronidazole addition: recommended when anaerobic coverage is needed or when concurrent bacterial vaginosis or trichomoniasis is present.

Note on ceftriaxone dose: The 2021 CDC STI guidelines updated the outpatient ceftriaxone dose to 500 mg (from the older 250 mg). Use 1 g IM if the patient weighs >150 kg.

Inpatient (Parenteral) Regimens

Regimen A (Preferred)

Regimen B (Preferred)

Regimen C (Preferred)

Regimen D (Clindamycin-Aminoglycoside)

Doxycycline is preferred orally even for inpatients because IV administration causes infusion pain, and oral bioavailability is equivalent.

Alternative Parenteral

• Ampicillin/sulbactam 3 g IV every 6 hours + doxycycline 100 mg PO or IV every 12 hours (good additional coverage for anaerobes and TOA with bowel involvement)

Transition from IV to Oral Therapy

• Switch from IV to oral 24-48 hours after clinical improvement (defervescence, reduction in tenderness)
• Complete oral regimen with doxycycline 100 mg PO twice daily to complete 14 days total
• If clindamycin-gentamicin was used IV, transition to oral clindamycin 450 mg four times daily or doxycycline 100 mg twice daily to complete 14 days
• For TOA: at least 24 hours of inpatient observation; oral clindamycin (450 mg QID) preferred over doxycycline to improve anaerobic coverage

Special Situations

IUD in situ

• IUD does not need to be removed automatically
• Treat with standard regimens and monitor closely
• If no clinical improvement within 48-72 hours, consider IUD removal

Fluoroquinolones

• No longer recommended as first-line due to widespread fluoroquinolone-resistant N. gonorrhoeae
• A 2025 meta-analysis (PMID: 41327742) found fluoroquinolones modestly improved cure rates (66% vs 62%) and had fewer adverse effects than comparators, but safety concerns (tendon damage, cardiovascular, neuropsychiatric effects) and resistance remain limiting factors

HIV-positive patients

• Same regimens as HIV-negative patients
• May experience more severe symptoms

Pregnancy

• Hospitalize and treat with IV regimens (avoid doxycycline if possible in early pregnancy; use azithromycin as an alternative for chlamydia coverage)

Tubo-Ovarian Abscess (TOA)

• Medical management first with IV antibiotics (ampicillin/sulbactam + doxycycline is favored, or clindamycin-gentamicin)
• If no improvement within 72 hours, image-guided aspiration/drainage (transvaginal or CT-guided) - success in up to 90% of cases
• Surgery (laparoscopy or laparotomy) reserved for ruptured TOA or failed drainage

Monitoring and Follow-up

• Expect clinical improvement (fever reduction, decreased tenderness) within 72 hours; if not, re-evaluate, confirm diagnosis, and switch to IV if outpatient
• Retest for gonorrhea and chlamydia 3 months after treatment
• Treat all sex partners who had contact within the 60 days before symptom onset for both gonorrhea and chlamydia empirically

Key Complications Without Treatment

• Tubal occlusion/infertility (~10% after 1 episode, rising to 20-30% with repeated episodes)
• Ectopic pregnancy (6-10× increased risk)
• Chronic pelvic pain
• Fitz-Hugh-Curtis syndrome (perihepatitis)